Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST –
TSX-V: ACST), a biopharmaceutical innovator focused on the
research, development and commercialization of its prescription
drug candidate CaPre® (omega-3 phospholipid) for the treatment of
severe hypertriglyceridemia (sHTG) (triglyceride blood levels from
500 mg/dL to 1500 mg/dL), today provided a business and TRILOGY
Phase 3 Clinical Program update, and announced its operating and
financial results for the fiscal year ended March 31, 2020.
The Company also reported a phenomenon that it
refers to as “Pre-Randomization Triglyceride (TG) Normalization”
that occurred between the screening and randomization periods of
the study (during qualification), and prior to patients starting on
drug or placebo. A summary of the post-hoc data analyses and
audit findings for TRILOGY 1 can be found below, and in the
Business Section of the Company’s annual report on Form
10-K, which will be filed with the Securities and Exchange
Commission today, and will be available on the Company’s
website.
Recent Corporate
Highlights:
- Reported topline results for
TRILOGY 1 Phase 3 trial of CaPre in January 2020
- Completed clinical site and central
lab audits in fiscal Q4
- Meeting request filed with the Food
and Drug Administration (FDA) to discuss TRILOGY 1 post-hoc data
analysis, with request to get input on proposed revisions to the
pre-specified Statistical Analysis Plan (SAP) for the TRILOGY 2
Phase 3 trial of CaPre
- Submitted briefing package with
TRILOGY 1 data to FDA on April 29, 2020
- Written response received from the
FDA and reported on June 19, 2020
- TRILOGY 2 topline results still
expected in calendar Q3
TRILOGY 1 Post-Hoc Review
Highlights:
- Rigorous post-hoc analysis of the
data conducted by the Company, the academic Principal Investigator
(PI) of the study, Dariush Mozaffarian M.D., Dr.P.H., and external
clinical and statistical experts
- Analysis of the TRILOGY 1 data
revealed a rapid, significant and sustained reduction in TG levels
between screening (during qualification) and the time of patient
randomization (prior to patients starting on either drug or
placebo), which Acasti refers to as “Pre-randomization TG
Normalization”
- Pre-Randomization TG Normalization
affected both treatment groups, but was much greater in the placebo
group, resulting in a significant underestimation of the
post-randomization treatment effect of the active drug, CaPre
- Company conducted post-hoc analyses
of the primary endpoint using a revised, single point baseline
value from Week 0 (Visit 4) which corrected for a significant
amount of the pre-randomization TG reduction in subjects that were
most affected by this normalization phenomenon
- Meaningful efficacy trend for CaPre
observed, after correcting for the unexpectedly large placebo
response in the original analysis
TRILOGY 1 Summary:
The Company released topline results from its
TRILOGY 1 Phase 3 trial in January 2020, reporting a 30.5% median
reduction in triglyceride levels among patients receiving CaPre at
12 weeks, and a 42.2% median reduction in triglyceride levels among
patients receiving CaPre while on background statin therapy at 12
weeks. Additionally, the Company reported a 36.7% median reduction
in triglyceride levels among patients receiving CaPre at 26 weeks.
Despite positive results in the CaPre arm, TRILOGY 1 did not reach
statistical significance due to an unusually large placebo response
of 27.5% and 28.0% median reductions in triglyceride levels at 12
and 26 weeks, respectively. The safety profile of CaPre in TRILOGY
1 was similar to placebo, as there was no significant difference in
treatment-related serious adverse events in the trial.
The protocol for TRILOGY 1 and 2 had input from
and was approved by the FDA, and followed essentially the same
standard design as has been used by all other companies running
trials in sHTG. There were some slight differences in the TRILOGY 1
patient population as compared to previous studies with other
omega-3 therapeutics in sHTG, but none that were believed to have
contributed to the significant placebo effect. As previously
reported, despite monitoring activities conducted throughout the
TRILOGY 1 trial to ensure adherence to the protocol and to detect
potential protocol violations, Acasti subsequently identified some
unexpected and inconsistent findings that the Company believes may
have negatively contributed to the unusual placebo effect. These
findings were further explored via a comprehensive and rigorous
post-hoc review of the data by the Company, the academic Principal
Investigator (PI) of the study, Dariush Mozaffarian M.D., Dr.P.H.,
and external clinical and statistical experts, as well as audits of
the central blood testing laboratory and certain clinical sites,
which were conducted by an independent team of auditors.
This post-hoc analysis of the TRILOGY 1 data
revealed a rapid, significant and sustained reduction in TG levels
during the patient qualification period, which took place between
screening and the time of patient randomization (that is, prior to
patients starting on either drug or placebo). Acasti refers to this
phenomenon as “Pre-Randomization TG Normalization.” This
phenomenon, which to our knowledge has not been reported in any
other TG studies, resulted in an artefactual overestimation of TG
reduction in both treatment groups. However, the Pre-Randomization
TG Normalization was much greater in the placebo group as compared
to the CaPre group, resulting in a significant underestimation of
the post-randomization treatment effect of CaPre in TRILOGY 1, and
further compromising the ability of the study to detect a
clinically significant drug treatment effect.
TG values are normally quite variable, and it is
expected that the intra-individual TG variation in subjects on a
healthy, low fat National Cholesterol Education Program (NCEP) diet
may be 10% or greater (going in either direction) within a one to
two week period. Thus, it is standard practice to include 2 or 3
pre-randomization TG measurements in the determination of the
baseline for the calculation of the primary endpoint. The
pre-randomization reduction in TGs across all subjects in TRILOGY 1
was about 20%, with 25% of all subjects experiencing a reduction
equal to or greater than 38%. The median Pre-Randomization TG
Normalization reached 30% or more in 12 out of 54 sites (or in 22%
of all randomizing sites), in all, much greater than the 10%
variation that would have been expected based on physiological
variability. In addition, natural variability would have resulted
in both increases and decreases in individual levels which would
largely offset each other, limiting aggregate variability below
10%. The magnitude of pre-randomization reduction in TG levels seen
in TRILOGY 1 indicated a largely unidirectional variability, which
was not likely due solely to physiological intra-individual
variation, and therefore is considered to be artefactual.
The unexpected and large magnitude of this
Pre-Randomization TG Normalization phenomenon resulted in about 40%
of all randomized and eligible subjects having TG levels at
randomization (Visit 4 or “Week 0") that fell below the protocol
specified average qualification lower threshold of ≥ 500 mg/dL for
patients with sHTG.
Based on the above observations, we believe that
the Pre-Randomization TG Normalization substantially impacted the
outcome of TRILOGY 1, and the ability of the study to accurately
determine the therapeutic impact of CaPre as measured by the
pre-specified primary endpoint. Specifically, we believe that the
use of an average of 3 values for the calculation of the baseline
TG levels corresponding to time points during Qualification (e.g.
at Week minus 2, and Week minus 1 prior to randomization), and Week
0 (at randomization), resulted in an overestimation of the TG
reduction, particularly in the placebo group – with significant TG
reduction occurring in many patients even before either drug or
placebo were started.
The Company conducted post-hoc analyses of the
primary endpoint using a revised, single point baseline value from
Week 0 (Visit 4), the date of randomization, which is referred to
as the “Revised Baseline.” Furthermore, only those subjects meeting
the protocol-specified TG threshold of ≥ 500 mg/dL and ≤ 1500 mg/dL
at Week 0 were included in this post-hoc analyses.
This revised approach for calculating the
baseline TG levels corrected for a significant amount of the
pre-randomization TG reduction in the subjects that were most
affected by this normalization phenomenon. After patients with TG
values <500 mg/dL and >1500 mg/dL on the date of
randomization were removed, a total of 143 subjects remained
(originally N = 242), including 42 subjects in the placebo group
(originally N = 69), and 101 subjects remained in the CaPre group
(originally N = 173), and were included in the post-hoc analyses
representing 61% and 58% of all randomized subjects,
respectively.
In this post-hoc analysis of subjects with TG
levels meeting the protocol specified TG threshold of >500 mg/dL
and <1500mg/dL at Week 0, subjects receiving CaPre showed a
28.1% median reduction in TG compared to a 15.4% median reduction
among subjects receiving placebo after 12 weeks (this represents
the primary endpoint, and a non-adjusted absolute difference of
12.7%; p = 0.29). As compared to the original analysis, the Revised
Baseline attenuated the placebo response by approximately 12
percentage points (from -27.5% to -15.4%), while the response in
the CaPre arm remained mostly unaffected (reduced from -30.0% to
-28.1%). After 26 weeks of double-blind treatment, the efficacy of
CaPre showed good persistency of effect with a 32.6% median
reduction compared with a 14.6% median reduction in the placebo
group, reaching a non-adjusted difference of -18.0%, which trended
toward statistical significance (p = 0.089). As compared to the
original analysis, the Revised Baseline attenuated the placebo
response at 26 weeks by approximately 13 percentage points (from
-28.0% to -14.6%), while the response in the CaPre arm remained
mostly unaffected (reduced from -36.7% to -32.6%). The median TG
reductions seen with CaPre using this post-hoc methodology compare
favorably to those of previous published studies of other FDA
approved drugs for sHTG.
The subgroup of subjects with Revised Baseline
TG levels above 750 mg/dL at Visit 4 (Week 0) represented 41% of
the subjects retained in the post-hoc analyses. Within this
group, the median TG reduction in the subjects receiving CaPre was
larger as would be expected, reaching 36.3% and 43.0% at Week 12
and Week 26, respectively. In comparison, the median TG reduction
for the placebo group was 11.8% at Week 12 and 14.4% at Week 26,
resulting in non-adjusted differences of 24.5% and 28.6%
respectively in favor of CaPre (p = 0.22 and 0.15,
respectively).
Not surprisingly, a post-hoc power calculation
revealed that these substantially smaller sample sizes resulted in
reduced statistical power to detect a treatment difference of 20%
as specified in the original Statistical Analysis Plan (SAP).
However, the Company believes that these post-hoc results suggest
clinical relevance even if statistical significance was not
demonstrated, as it is plausible that the trend revealed in the
post-hoc analysis may have achieved statistical significance with a
larger sample size.
In summary, the post-hoc analyses of TRILOGY 1
data using the Week 0 (Visit 4) value as a Revised Baseline in
subjects with TG ≥ 500 mg/dL and ≤ 1500 mg/dL at Week 0, showed a
strong trend towards correcting for the unexpectedly large placebo
response observed in the original analysis, without major changes
in the CaPre response observed, and we believe allows for a clearer
understanding of the impact on the TG primary endpoint, and the
potential therapeutic effect of CaPre. However, the median
difference in TG levels between CaPre and placebo from the TRILOGY
1 post-hoc analyses still fell short of reaching statistical
significance at the Week 12 primary endpoint in this patient
adjusted sample.
“The originally observed large reduction in TG
in the placebo group was extremely unusual,” said Dr. Mozaffarian,
PI of the TRILOGY study. “For unclear reasons, perhaps regression
to the mean, many of the patients in the placebo group experienced
large reductions in TG even before being randomized. Use of
the single baseline TG value at the time of randomization, in a
post-hoc analysis, greatly attenuated and appears to explain much
of this unusual placebo response. We look forward to the
results of TRILOGY 2, which will further clarify the TG lowering
effects of CaPre.”
The Company provided all of the TRILOGY 1
background information and accompanying data to the FDA in a Type C
briefing package which was filed on April 29, 2020. The FDA
provided Acasti with a written response to its Type C Meeting
request and briefing package, and confirmed that it will require
pivotal efficacy analyses for TRILOGY 2 to be performed on the full
Intent to Treat (ITT) population, as contemplated in the original
Statistical Analysis Plan (SAP), and they supported the conduct of
post-hoc analyses in TRILOGY 1 for exploratory purposes. Consistent
with the Company’s prior disclosures, and depending on the outcome
of TRILOGY 2, an additional clinical study may still be needed
prior to submitting a New Drug Application (NDA). Acasti and its
expert advisors are now carefully considering the FDA’s comments on
the TRILOGY 1 data and will conduct further post-hoc analysis based
on their feedback.
Jan D’Alvise, president and CEO of Acasti,
commented, “We made steady progress throughout fiscal 2020 by
completing our TRILOGY Phase 3 trials in fiscal Q4, and advancing
other important pre-commercialization activities, including
scale-up of our manufacturing, NDA preparation, and certain
partnering and market development objectives. While our initial
topline results from TRILOGY 1 were disappointing due to the
unusually large placebo effect, we now have a better understanding
of the unusual “Pre-Randomization TG Normalization effect” that
contributed significantly to the TRILOGY 1 outcome. We are
carefully considering the FDA’s comments on the TRILOGY 1 data, and
are conducting further post-hoc analysis based on their feedback.
Acasti will now finalize the Statistical Analysis Plan (SAP) for
TRILOGY 2, which we plan to submit to the FDA by the end of July.
We continue to remain blinded to the TRILOGY 2 data, and we
continue to estimate that we should be able to report topline data
by the end of August 2020. The key secondary and exploratory
endpoints from both TRILOGY 1 and TRILOGY 2 trials would still be
expected as soon as possible after the unblinding of TRILOGY 2
results.”
D’Alvise continued, “In parallel with all of the
TRILOGY activities in Fiscal 2020, we continued to make good
progress on the preparation of our NDA package, and plans for
commercial launch in the United States, assuming we are successful
in gaining regulatory approval for CaPre. At the same time, we
continued to strengthen our intellectual property portfolio. We are
pleased to have been awarded additional composition of matter and
method of use patents in Canada, United States, Mexico, China, Hong
Kong, Chile, and Israel since the start of fiscal 2020. We believe
all of these patents and pending patent applications increase
potential commercial opportunities for CaPre, including through
possible licensing and partnership opportunities. We are committed
to building a global portfolio of patents to ensure long-lasting
and comprehensive intellectual property protection, and to
safeguard potentially valuable market expansion opportunities.”
As of March 31, 2020, Acasti had cash, cash
equivalents and short-term investments totaling $14.2 million,
compared to $25.8 million as of March 31, 2019. The Company
believes it is sufficiently funded into the first calendar quarter
of 2021, based on management’s current projections.
Other Developments:
- On April 20, 2020, Acasti announced receiving
a Notice of Allowance for its second composition of matter patent
to be awarded by the Canadian Intellectual Property Office. This
new patent expands the Company’s existing claims to include any
composition containing EPA and DHA, where at least 50% of the
composition consists of phospholipids.
- On April 30, 2020, Acasti reported receiving a
notice of issuance of a composition of matter patent to be awarded
by the Intellectual Property Office in Hong Kong granting claims
for any composition containing EPA and DHA, where at least 50% of
the composition consists of phospholipids.
Fiscal Year 2020 Financial Results (US
dollars):
The consolidated financial statements have been
prepared in accordance with generally accepted accounting
principles in the United States of America (“U.S. GAAP”).
- Loss from operations for the year ended March
31, 2020 was $24.4 million, compared to a loss from operations of
$34.4 million for the year ended March 31, 2019. The decrease was
due mainly to a reduction in research contract expenses as the
Phase 3 clinical program for CaPre was nearing completion.
- Net loss for the year ended March 31, 2020 was
$25.5 million or $0.30 per share, compared to a net loss of $39.4
million or $0.73 per share for the year ended March 31, 2019. The
decreased net loss is primarily due to the reduction of research
and development expenses as the Phase 3 clinical program for CaPre
was nearing completion, lower net financial expenses, and to the
change in fair value of the warrant derivative liability.
- R&D expenses before depreciation,
amortization and stock-based compensation expenses were $13.2
million for the year ended March 31, 2020, compared to $26.9
million for the year ended March 31, 2019. The $13.6 million
decrease was mainly attributable to a $14.4 million decrease in
research contracts, partially offset by an increase in salaries and
benefits due to increased headcount and related benefits. The lower
research contract expense is primarily attributed to the Phase 3
clinical trial program nearing completion.
- General and Administrative expenses before
stock-based compensation expenses were $4.6 million for the year
ended March 31, 2020, an increase of $1.3 million from $3.3 million
for the year ended March 31, 2019. This increase was mainly
attributable to a $0.45 million increase associated with the
Company’s insurance policies, as well as an increase of $0.83
million in corporate, accounting and legal fees associated with the
implementation of a new ERP system, and the conversion of the
financial reporting from IFRS to U.S. GAAP.
- Sales and Marketing expenses before
stock-based compensation expenses were $2.4 million for the year
ended March 31, 2020, compared to $0.42 million for the year ended
March 31, 2019. The increase is in line with the planned increased
headcount in the commercial team to support expanded business and
market development activities.
- Cash flows – Cash and cash equivalents and
short-term investments totaled $14.2 million as of March 31, 2020,
compared to $25.8 million for the year ended March 31, 2019. As
stated above, Acasti believes that existing cash will fully fund
the Company’s operations into the first calendar quarter of 2021.
Acasti projects that additional funds will be needed in the future
for activities necessary to prepare for the commercial launch of
CaPre if regulatory approval is received, including the scale-up of
its manufacturing operations, the completion of the potential
regulatory NDA submission package (assuming positive Phase 3
clinical results), and the expansion of business development and
U.S. commercial launch activities. The Company is working towards
development of strategic partner relationships, as well as actively
seeking additional non-dilutive funds in the near future, but there
can be no assurance as to when or whether Acasti will complete any
strategic collaborations or non-dilutive financings. If the Company
does not raise additional funds or find one or more strategic
partners, it may not be able to realize its assets and discharge
its liabilities in the normal course of business. As a result,
there exists substantial doubt about the Company’s ability to
continue as a going concern, and therefore, realize its assets and
discharge its liabilities in the normal course of business.
Capital Markets
Update:
Acasti provided an update on recent
distributions under its previously adopted “at-the-market” equity
offering program (the “ATM Program”), as required pursuant to the
policies of the TSX Venture Exchange. Since the last distributions
under the ATM program reported on February 14, 2020, Acasti issued
an aggregate of 2,278,936 common shares (the “ATM Shares”) over the
NASDAQ Stock Market for aggregate gross proceeds to the Company of
US$ 1.8 million. The ATM Shares were sold at prevailing market
prices averaging US$ 0.81 per share. No securities were sold
through the facilities of the TSX Venture Exchange or, to the
knowledge of the Company, in Canada. The ATM Shares were sold
pursuant to a U.S. registration statement on Form F-3 (No.
333-223464) as made effective on March 16, 2018, as well as an
at-the-market issuance sales agreement dated February 14, 2019
among Acasti and B. Riley FBR, Inc. In addition, 81,925 common
shares of the Company were issued over the NASDAQ Stock Market on
December 13, 2019 for additional aggregate gross proceeds to the
Company of US$167,946.25, which issuance was unintentionally
omitted from the press release dated February 14, 2020 referenced
above.
Conference
Call
Acasti will host a conference call today, June
29, 2020 at 1:00 PM Eastern Time to discuss the Company’s financial
results for the year ended March 31, 2020, as well as provide an
update on the TRILOGY Phase 3 program for CaPre.
The conference call will be available via
telephone by dialing toll free 844-369-8770 for U.S. callers or +1
862-298-0840 for international callers, or on the Company’s News
and Investors section of the website:
https://www.acastipharma.com/investors/.
A webcast replay will be available on the
Company’s News and Investors section of its website
(https://www.acastipharma.com/investors/) through September 29,
2020. A telephone replay of the call will be available
approximately one hour following the call, through July 6, 2020,
and can be accessed by dialing 877-481-4010 for U.S. callers or +1
919-882-2331 for international callers and entering conference ID:
35330.
About CaPre (omega-3
phospholipid)
Acasti’s prescription drug candidate, CaPre, is
a highly purified omega-3 phospholipid concentrate derived from
krill oil, and is being developed to treat severe
hypertriglyceridemia, a metabolic condition that contributes to
increased risk of cardiovascular disease and pancreatitis. Its
omega-3s, principally EPA and DHA, are either “free” or bound to
phospholipids, which allows for better absorption into the body.
Acasti believes that EPA and DHA are more efficiently transported
by phospholipids sourced from krill oil than the EPA and DHA
contained in fish oil that are transported either by triglycerides
(as in dietary supplements) or as ethyl esters in other
prescription omega-3 drugs, which must then undergo additional
digestion before they are ready for transport in the bloodstream.
Clinically, the phospholipids may not only improve the absorption,
distribution, and metabolism of omega-3s, but they may also
decrease the synthesis of LDL cholesterol in the liver, impede or
block cholesterol absorption, and stimulate lipid secretion from
bile. In two Phase 2 studies, CaPre achieved a statistically
significant reduction of triglycerides and non-HDL cholesterol
levels in patients across the dyslipidemia spectrum from patients
with mild to moderate hypertriglyceridemia (patients with TG blood
levels between 200mg/dl and 500mg/dl) to patients with severe
hypertriglyceridemia (those with TG levels above 500mg/dl).
Furthermore, in the Phase 2 studies, CaPre demonstrated the
potential to actually reduce LDL, or “bad cholesterol”, as well as
the potential to increase HDL, or “good cholesterol”, especially at
the therapeutic dose of 4 grams/day. The Phase 2 data also showed a
significant reduction of HbA1c at a 4-gram dose, suggesting that
due to its unique omega-3/phospholipid composition, CaPre may
actually improve long-term glucose metabolism. Acasti’s TRILOGY
Phase 3 program is currently underway, as noted above.
About Acasti
Acasti is a biopharmaceutical innovator
advancing a potentially best-in-class cardiovascular drug, CaPre,
for the treatment of hypertriglyceridemia, a chronic condition
affecting an estimated one third of the U.S. population. Since its
founding in 2008, Acasti has focused on addressing a critical
market need for an effective, safe and well-absorbing omega-3
therapeutic that can make a positive impact on the major blood
lipids associated with cardiovascular disease risk. The Company is
developing CaPre in a Phase 3 clinical program in patients with
severe hypertriglyceridemia, a market that includes 3 to 4 million
patients in the U.S. The potential exists to expand the treatable
market in the United States to the approximately 50 million people
with TGs above 150 mg/dl, given the recent FDA approval of expanded
labeling for VASCEPA based on the recent positive REDUCE-IT outcome
study results. Acasti may need to conduct at least one additional
clinical trial to support FDA approval of a supplemental New Drug
Application to expand CaPre’s indications to this segment. Acasti’s
strategy is to commercialize CaPre in the U.S. and the Company is
pursuing development and distribution partnerships to market CaPre
in major countries around the world. For more information, visit
www.acastipharma.com.
Forward
Looking
Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking information” within the meaning of Canadian
securities laws and “forward-looking statements” within the meaning
of U.S. federal securities laws (collectively, “forward-looking
statements”). Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Acasti to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms “believes,” “belief,”
“expects,” “intends,” “anticipates,” “potential,” “should,” “may,”
“will,” “plans,” “continue”, “targeted” or other similar
expressions to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Forward-looking statements in this press release include, but are
not limited to, information or statements about Acasti’s strategy,
future operations, prospects and the plans of management; Acasti’s
ability to conduct all required clinical and non-clinical trials
for CaPre, including the timing and results of those trials;
CaPre’s potential to become the “best-in-class” cardiovascular drug
for treating severe Hypertriglyceridemia; the timing and outcome of
the unblinding of TRILOGY 2; and Acasti’s ability to file an NDA
based on the results of its TRILOGY Phase 3 program.
The forward-looking statements contained in this
press release are expressly qualified in their entirety by this
cautionary statement, the “Special Note Regarding Forward-Looking
Statements” section contained in Acasti’s latest annual report on
Form 10-K, which will be available on EDGAR at
www.sec.gov/edgar/shtml, on SEDAR at www.sedar.com and on the
investor section of Acasti’s website at www.acastipharma.com. All
forward-looking statements in this press release are made as of the
date of this press release. Acasti does not undertake to update any
such forward-looking statements whether as a result of new
information, future events or otherwise, except as required by law.
The forward-looking statements contained herein are also subject
generally to assumptions and risks and uncertainties that are
described from time to time in Acasti’s public securities filings
with the Securities and Exchange Commission and the Canadian
securities commissions, including Acasti’s latest annual report on
Form 10-K under the caption “Risk Factors”.
Neither NASDAQ, the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Acasti
Contact:
Jan D’AlviseChief Executive OfficerTel:
450-686-4555Email: info@acastipharma.comwww.acastipharma.com
Investor
Contact:
Crescendo Communications, LLCTel:
212-671-1020Email: ACST@crescendo-ir.com
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Apr 2023 to Apr 2024